An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

Phase 2

• Conditions: Targeted Therapy; Immunotherapy; Gastrointestinal Cancer
• Interventions: Drug: Camrelizumab; Drug: Apatinib Mesylate

• Registration Number: NCT05225844
• Lead Sponsor: Harbin Medical University

Brief Summary

At present, surgery, radiotherapy and chemotherapy are the main treatment methods for patients with advanced gastrointestinal cancer. Although targeted therapy has significantly improved the prognosis of patients, the mortality of patients has not been significantly reduced, so new treatment methods are urgently needed. In recent years, immunotherapy has become a new hotspot in tumor therapy. Compared with traditional treatment, immune checkpoint inhibitors (ICIS) have shown long-term good efficacy and tolerance in clinical trials. However, single drug ICIS has reached a bottleneck for advanced gastrointestinal cancer, with low response rate and poor PFS and OS. With the results of REGONIVO showing good efficacy, the treatment mode of immune combined with small molecule anti angiogenesis drugs has sprung up. The purpose of this study was to analyze the efficacy and safety of in Camrelizumab combination with Apatinib mesylate in advanced gastrointestinal cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-01
• Study First Submitted: 2022-01-24
• Status Verified: 2022-02
• Primary Completion: 2022-02-01
• Study First Submitted QC: 2022-02-04
• Last Update Submitted: 2022-02-04
• Study First Posted: 2022-02-07
• Last Update Posted: 2022-02-07
• Study Completion: 2022-10-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• 1. Diagnosed as gastric or colorectal adenocarcinoma by histopathology and/or cytology.

  2. Patients could not receive surgical resection. 3. Previous standard treatment failure . 4. According to the RECIST v1.1 guide, at least 1 lesions (never received radiotherapy),accurately measured by computed tomography (CT) or magnetic resonance imaging (MRI) (intravenous contrast agent as the first choice),the longest diameter was more than 10mm (except for the lymph nodes, the short axis of the lymph nodes must be more than 15mm), repeated measurement.

  5.Eastern Cooperative Oncology Group Performance Status(ECOG PS):0-1 score 6.The main organs function is normal, which meets the following requirements. (1) Blood routine examination,(no blood transfusion within 14 days).

  1. Hemoglobin(HB)≥90g/L;
  2. Absolute neutrophil count (ANC) ≥1.5×10^9/L;
  3. Blood platelet (PLT)≥80×10^9/L; (2) Biochemical examination should comply with the following criteria:
  <!-- -->
  1. Bilirubin(BIL) <1.5 times of the upper limit of normal value (ULN)
  2. Alanine aminotransferase (ALT) and aspartate aminotransferase(AST)<2.5*ULN (liver metastasis ALT and AST<5*ULN).
  3. Serum Cr≤1*ULN, creatinine clearance rate≥50ml/min(Cockcroft-Gault formula) 7. The expected survival time more than 3 months; 8. The physicians plan to use Camrelizumab Plus Apatinib Mesylate. 9. Patients voluntarily joined the study and signed informed consent form(ICF). 10. Childbearing age women must undergo a negative pregnancy test(serum or urine) within 7 days ,and voluntarily adopt appropriate methods for contraception from the period of under observation and within 8 weeks of the last time they are given the drug;As for men, it is necessary to receive surgical sterilization, or agree to adopt appropriate methods for contraception from the period of under observation and within 8 weeks of the last time they are given the drug.

Exclusion Criteria

1. There is a case of heart disease in any of the following situations. (1)Recent publications have the following heart disease (within 6 months)

   1. Acute coronary artery syndrome

   2. Acute heart failure (grade III or IV of NYHA classification)

   3. Significant ventricular arrhythmia(sustained ventricular tachycardia, ventricular fibrillation and sudden death after resuscitation).

      (2)The New York Heart Association(NYHA) grade of grade III or IV (3)The patients with severe conduction block, and permanent pacemaker is invalid (two degree and three degree atrioventricular block, sinus arrest) (4)Unexplained syncope occurred within 3 months.

      (5)The researchers identified as uncontrol of severe hypertension, or symptomatic hypertension.

2. There are many factors that affect the absorption of oral drugs (such as unable to swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction).

3. ECOG score≥2

4. Abnormal coagulation function (INR>1.5*ULN, Activated Partial Thromboplastin Time (APTT)>1.5*ULN), with bleeding tendency.

5. There is any history of allergy or hypersensitivity in this research's drug or adjuvant.

6. HIV infection and/or active hepatitis B virus infection.

7. Any condition that may damage the safety of patients or the integrity of research data, including serious medical risk factors, physical condition and laboratory abnormality.

8. The high risk population carrying UGT1A1*28 (7/7) *6 (A/A) genotype or simultaneous carrying of the UGT1A1*28 (6/7) *6 (A/G) genotype (the heterozygous genotype) suggests the exclusion of the Irinotecan

9. Pregnant or lactating women;

10. Other conditions which the doctor think not suitable for inclusion.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Camrelizumab and Apatinib mesylate	Apatinib Mesylate	for advanced colorectal cancer with previous standard treatment failure
Camrelizumab Plus Apatinib mesylate	Apatinib Mesylate	for advanced gastric cancer with previous standard treatment failure
Camrelizumab Plus Apatinib mesylate	Camrelizumab	for advanced gastric cancer with previous standard treatment failure
Camrelizumab and Apatinib mesylate	Camrelizumab	for advanced colorectal cancer with previous standard treatment failure

Primary Outcome Measures

Name	Time	Method
Objective response rate (ORR)	24 months	The proportion of patients whose tumor is reduced to a certain amount and maintain a certain period of time.
progression-free survival（PFS）	24 months	the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier)

Secondary Outcome Measures

Name	Time	Method
Adverse Events	24 months	Adverse events will be evaluated according to NCI CTCAE 4.0
Disease control rate(DCR)	24 months	The rate of cases of remission and stable disease accounts for the total evaluable cases after treatment
Overall Survival（OS）	24 months	overall survival time after the beginning of the treatment

Trial Locations

Locations (1)

Harbin Medical University; 🇨🇳 Harbin, Heilongjiang, China